Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Machold, KP; Landewé, R; Smolen, JS; Stamm, TA; van der Heijde, DM; Verpoort, KN; Brickmann, K; Vázquez-Mellado, J; Karateev, DE; Breedveld, FC; Emery, P; Huizinga, TW.
The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis.
Ann Rheum Dis. 2010; 69(3): 495-502. Doi: 10.1136/ard.2009.122473
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Brickmann Kerstin
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Background Glucocorticoids (GCs) are often used as early arthritis treatment and it has been suggested that they induce remission or at least delay the development of rheumatoid arthritis (RA) and the need to start disease-modifying antirheumatic drugs (DMARDs). Objective To test the effect of GCs on patients with very early arthritis (symptom duration of <16 weeks) in a randomised controlled trial. Methods Patients received a single intramuscular injection of 120 mg methylprednisolone or placebo (PL) and were followed up for 52 weeks. Primary end point was drug-free clinical remission, both at weeks 12 and 52. Among secondary outcomes were fulfilment of remission criteria at weeks 2, 12 or 52, time course of 'core set variables' and proportion of patients starting DMARDs. Results 17.0% of all analysed subjects (65/383) achieved persistent remission: 17.8% (33/185) of the PL group, 16.2% (32/198) of the patients receiving methylprednisolone (OR = 1.13, 95% CI 0.66 to 1.92, p = 0.6847). Analyses of secondary end points showed significant clinical benefits of the GC only at week 2. These differences subsequently disappeared. DMARDs were started in 162 patients: 50.3% methylprednisolone and 56.7% PL patients had to start DMARD treatment (OR = 0.78, 95% CI 0.49 to 1.22, p = 0.30). Significantly more patients with polyarthritis than with oligoarthritis received DMARDs (OR = 2.84, 95% CI 1.75 to 4.60, p<0.0001). Conclusions Neither remission nor development of RA is delayed by GC treatment. Remission is rare in the first year of very early arthritis, occurring in <20% of the patients. Also, the need to start DMARDs was not influenced by GC treatment.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Aged -; Aged, 80 and over -; Anti-Inflammatory Agents - administration and dosage; Antirheumatic Agents - administration and dosage; Arthritis - drug therapy; Drug Therapy, Combination -; Epidemiologic Methods -; Female -; Glucocorticoids - administration and dosage; Humans -; Male -; Methylprednisolone - administration and dosage; Middle Aged -; Remission Induction -; Young Adult -